Axon Enterprise, Inc (NASDAQ:AXON) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have earned an average rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $763.75.

A number of brokerages have issued reports on AXON. The Goldman Sachs Group increased their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. UBS Group began coverage on Axon Enterprise in a research report on Wednesday. They set a “neutral” rating and a $820.00 price target on the stock. Needham & Company LLC increased their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Finally, JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday.

Axon Enterprise Stock Up 1.4%

Shares of AXON opened at $756.09 on Friday. Axon Enterprise has a 52 week low of $279.02 and a 52 week high of $830.21. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $58.86 billion, a price-to-earnings ratio of 182.63, a PEG ratio of 85.86 and a beta of 1.29. The stock’s 50-day moving average price is $763.54 and its 200-day moving average price is $645.61.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the business earned $1.15 earnings per share. The company’s revenue was up 31.3% compared to the same quarter last year. On average, sell-side analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, President Joshua Isner sold 905 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total value of $702,632.95. Following the completion of the sale, the president owned 268,735 shares of the company’s stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Cameron Brooks sold 3,000 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the sale, the executive directly owned 19,447 shares of the company’s stock, valued at approximately $14,405,559.72. This represents a 13.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in AXON. Fourth Dimension Wealth LLC purchased a new position in Axon Enterprise in the fourth quarter worth approximately $30,000. TCTC Holdings LLC grew its position in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC grew its position in Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new position in Axon Enterprise in the first quarter worth approximately $32,000. Finally, Banque Transatlantique SA purchased a new position in Axon Enterprise in the first quarter worth approximately $31,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.